What is Opticyte?
Opticyte is at the forefront of medical innovation with its development of the VitalO₂, a revolutionary device capable of real-time, in-cell oxygen level measurement. This technology holds the potential to fundamentally alter the standard of care for conditions such as sepsis and organ failure, addressing critical healthcare disparities, particularly within communities of color. The VitalO₂ is engineered for deployment in high-acuity settings including emergency departments, intensive care units, and operating rooms, equipping clinicians with vital data for enhanced patient management and improved health outcomes.
How much funding has Opticyte raised?
Opticyte has raised a total of $4.6M across 2 funding rounds:
Grant
$2.9M
Angel/Seed
$1.7M
Grant (2020): $2.9M with participation from SBIR Phase IIB
Angel/Seed (2020): $1.7M led by Starfish Medical and SWAN Venture Fund II
Key Investors in Opticyte
Starfish Medical
Starfish Medical is a medical device design and development company, likely providing expertise and resources to advance Opticyte's innovative technology.
SWAN Venture Fund II
SWAN Venture Fund II is an investment vehicle that provides capital for promising ventures, indicating a financial backing for Opticyte's growth and market expansion.
What's next for Opticyte?
With the recent major strategic investment, Opticyte is poised for significant expansion and further development of its VitalO₂ technology. The company's focus on improving early detection and treatment of life-threatening conditions, coupled with a commitment to health equity, positions it for substantial growth. This latest round of financing will likely fuel advancements in clinical validation, market penetration, and the scaling of manufacturing capabilities to meet the anticipated demand from healthcare providers seeking to enhance patient care and outcomes.
See full Opticyte company page
